HARBOUR BIOMED

和鉑醫藥控股有限公司

HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT ENTERING INTO NON-EXCLUSIVE LICENSE AGREEMENT WITH PFIZER

This announcement is made by HBM Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that Nona Biosciences (Suzhou) Co., Ltd ("**Nona Biosciences**"), a subsidiary wholly-owned by the Company, and Pfizer have entered into a non-exclusive license agreement (the "**Agreement**"), which aims to accelerate preclinical antibody discovery across a range of potential disease indications.

Under the terms of the Agreement, Pfizer will gain global rights to access Nona Biosciences' proprietary HCAb platform to generate fully human heavy chain-only antibodies. Nona Biosciences will receive an upfront payment and is eligible for regulatory, clinical, and commercial milestone payments. In addition, Nona Biosciences may collaborate with Pfizer for antibody discovery, development, and engineering, leveraging Nona Biosciences' HCAb platform, advanced B-cell screening technologies, and integrated services.

Cautionary Statement

We cannot guarantee that we or our collaboration partners will be able to successfully develop or ultimately market any of the product candidates referenced in this announcement. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 19 November 2025

As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.